Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Neoplasms 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Glioblastoma 2Prostatic Neoplasms 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 133Gemcitabine 101Paclitaxel 100Carboplatin 84Nivolumab 66Docetaxel 62Bevacizumab 62Cisplatin 57Pemetrexed 50Fluorouracil 49Cyclophosphamide 41Cetuximab 41trametinib 38venetoclax 37Leucovorin 37Irinotecan 37Sorafenib 35Capecitabine 35Ipilimumab 33Dexamethasone 32atezolizumab 31Erlotinib Hydrochloride 28130-nm albumin-bound paclitaxel 28Drug Therapy 27Epoetin Alfa 26Doxorubicin 25Oxaliplatin 24Albumin-Bound Paclitaxel 24Prednisone 23Rituximab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms × TPI-287 × Clear all
NCT00113724 2009-06-04

Study of TPI 287 in Patients With Advanced Malignancies

Cortice Biosciences, Inc.

Phase 1 Completed
48 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

NCT00256191 2007-10-15

Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

Cortice Biosciences, Inc.

Phase 1 Completed
45 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡